Granted Patent
B2
US 12,440,680 · App. 17/692,807 · Granted Oct 14, 2025
Methods of treating disease by skewing macrophage phenotype with alternating electric fields
Inventors:
Tali Voloshin-Sela (Kibbutz Gvat, IL); Lilach Avigdor (Haifa, IL); Boris Brant (Haifa, IL)
Assignee:
Novocure GmbH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating diseases and infections by applying alternating electric fields to tissues followed by administering a treatment for the disease or infection are provided. In some instances, alternating electric fields can be applied at least until substantial improvement in disease manifestation. The exemplary methods can be used to treat kidney, heart, brain, and bone disease and conditions.
Claims (8)
1. A method of treating an infection in a subject, comprising:
applying alternating electric fields of frequency between 50 and 500 kHz and field strength of 0.1 to 10 V/cm to the subject; and
administering a therapeutically effective amount of an antibiotic for treating the infection to the subject; wherein the infection is with:
Tropheryma whipplei , or Salmonella in a digestive system and the alternating electric fields are applied to the digestive system of the subject.
2. The method of claim 1 , wherein the infection is with Tropheryma whipplei , or Salmonella in a digestive system of the subject, and wherein the antibiotic is selected from the group consisting of one or more of penicillin, streptomycin, tetracycline, ceftriaxone, meropenem, co-trimoxazole, doxycycline, hydroxychloroquine, fluoroquinolones, and azithromycin.
3. The method of claim 2 , wherein the frequency is between 125 and 175 kHz.
4. The method of claim 2 , wherein the alternating electric fields are applied for at least 24 hours.
5. The method of claim 2 , wherein the alternating electric fields are applied until the digestive system of the subject is not infected with Tropheryma whipplei , or Salmonella.
Assignments (2)
PATENT SECURITY AGREEMENT
Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 9, 2022
From: AVIGDOR, LILACH; VOLOSHIN-SELA, TALI; BRANT, BORIS
To: NOVOCURE GMBH
Reel/Frame 059871/0019 →
Continuity (2)
Provisional Application
63160437
· Mar 12, 2021
References Cited (125)
US 5233987A
· Fabian et al.
· 1993
[cited by applicant]
US 6868289B2
· Palti
· 2005
[cited by applicant]
US 7016725B2
· Palti
· 2006
[cited by applicant]
US 7089054B2
· Palti
· 2006
[cited by applicant]
US 7136699B2
· Palti
· 2006
[cited by applicant]
US 7333852B2
· Palti
· 2008
[cited by applicant]
US 7467011B2
· Palti
· 2008
[cited by applicant]
US 7519420B2
· Palti
· 2009
[cited by applicant]
US 7565205B2
· Palti
· 2009
[cited by examiner]
US 7565206B2
· Palti
· 2009
[cited by applicant]
US 7599745B2
· Palti
· 2009
[cited by applicant]
US 7599746B2
· Palti
· 2009
[cited by applicant]
US 7706890B2
· Palti
· 2010
[cited by applicant]
US 7715921B2
· Palti
· 2010
[cited by applicant]
US 7805201B2
· Palti
· 2010
[cited by applicant]
US 7890183B2
· Palti et al.
· 2011
[cited by applicant]
US 7912540B2
· Palti
· 2011
[cited by applicant]
US 7917227B2
· Palti
· 2011
[cited by applicant]
US 8019414B2
· Palti
· 2011
[cited by applicant]
US 8027738B2
· Palti
· 2011
[cited by applicant]
US 8170684B2
· Palti
· 2012
[cited by applicant]
US 8175698B2
· Palti et al.
· 2012
[cited by applicant]
US 8229555B2
· Palti
· 2012
[cited by applicant]
US RE43618E
· Palti
· 2012
[cited by applicant]
US 8244345B2
· Palti
· 2012
[cited by applicant]
US 8406870B2
· Palti
· 2013
[cited by applicant]
US 8447395B2
· Palti et al.
· 2013
[cited by applicant]
US 8447396B2
· Palti et al.
· 2013
[cited by applicant]
US 8465533B2
· Palti
· 2013
[cited by applicant]
US 8706261B2
· Palti
· 2014
[cited by applicant]
US 8715203B2
· Palti
· 2014
[cited by applicant]
US 8718756B2
· Palti
· 2014
[cited by applicant]
US 8764675B2
· Palti
· 2014
[cited by applicant]
US 9023090B2
· Palti
· 2015
[cited by applicant]
US 9023091B2
· Palti
· 2015
[cited by applicant]
US 9039674B2
· Palti et al.
· 2015
[cited by applicant]
US 9056203B2
· Palti et al.
· 2015
[cited by applicant]
US 9440068B2
· Palti et al.
· 2016
[cited by applicant]
US 9655669B2
· Palti et al.
· 2017
[cited by applicant]
US 9750934B2
· Palti
· 2017
[cited by examiner]
US 9910453B2
· Wasserman et al.
· 2018
[cited by applicant]
US 20160074480A1
· Shantha
· 2016
[cited by examiner]
US 20170266283A1
· Soikum
· 2017
[cited by examiner]
US 20180001075A1
· Kirson et al.
· 2018
[cited by applicant]
US 20180008708A1
· Giladi et al.
· 2018
[cited by applicant]
US 20190117963A1
· Travers et al.
· 2019
[cited by applicant]
US 20200009376A1
· Chang et al.
· 2020
[cited by applicant]
US 20200108031A1
· Borst et al.
· 2020
[cited by applicant]
US 20200121728A1
· Wardak et al.
· 2020
[cited by applicant]
US 20200146586A1
· Naveh et al.
· 2020
[cited by applicant]
US 20200179512A1
· Giladi et al.
· 2020
[cited by applicant]
US 20200269041A1
· Zeevi et al.
· 2020
[cited by applicant]
US 20200368525A1
· Maag et al.
· 2020
[cited by applicant]
US 20210069503A1
· Tran et al.
· 2021
[cited by applicant]
US 20210199640A1
· Patel et al.
· 2021
[cited by applicant]
US 20210299440A1
· Deslauriers et al.
· 2021
[cited by applicant]
US 20210308446A1
· Alon et al.
· 2021
[cited by applicant]
US 20210346694A1
· Wasserman et al.
· 2021
[cited by applicant]
US 20220161028A1
· Giladi et al.
· 2022
[cited by applicant]
US 20230009366A1
· Voloshin-Sela
· 2023
[cited by examiner]
WO 02068049A1
· 2002
[cited by applicant]
WO 2016172595A1
· 2016
[cited by applicant]
WO 2021137094A1
· 2021
[cited by applicant]
Lowrie et al., Division and Death Rates of
[cited by examiner]
Keles et al., Inactivation of
[cited by examiner]
Giladi in “Microbial Growth Inhibition by Alternating Electric Fields in Mice with Pseudomonas aeruginosa Lung Infection”, Antimicrobial Agents and Chemotherapy, pp. 3212-3218, published Aug. 1, 2010). (Year: 2010).
[cited by examiner]
Edin et al., “The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer,” PLoS One, vol. 7, No. 10, p. e47045, Oct. 2012.
[cited by applicant]
Feng et al., “Wnt/β-Catenin-Promoted Macrophage Alternative Activation Contributes to Kidney Fibrosis,” Journal of the American Society of Nephrology, vol. 29, No. 1, pp. 182-193, Jan. 2018.
[cited by applicant]
Giladi et al., “Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells,” Scientific Reports, vol. 5, p. 18046, Dec. 2015.
[cited by applicant]
Gombozhapova et al., “Macrophage activation and polarization in post-infarction cardiac remodeling,” Journal of Biomedical Science, vol. 24, No. 1, p. 13, Feb. 2017.
[cited by applicant]
Hirayama et al., “The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis,” International Journal of Molecular Sciences, vol. 19, No. 1, p. 92, Dec. 2017.
[cited by applicant]
International Search Report and Written Opinion issued in application PCT/IB2022/05226 dated Jun. 14, 2022.
[cited by applicant]
Mills et al.., “Macrophages at the fork in the road to health or disease,” Frontiers in Immunology, vol. 6, Article 59, Feb. 2015.
[cited by applicant]
Wang et al., “Molecular mechanisms that influence the macrophage M1-M2 polarization balance,” Frontiers in Immunology, vol. 5, Article 614, Nov. 2014.
[cited by applicant]
Wong et al., “Tumor treating fields exert cellular and immunologic effects,” Proceedings of the 109th Annual Meeting of the American Association for Cancer Research, Apr. 14-18, 2018, Chicago, Illinois, Abstract nr1707.
[cited by applicant]
Yunna et al., “Macrophage M1/M2 polarization,” European Journal of Pharmacology, vol. 877, p. 173090, Jun. 2020.
[cited by applicant]
Giladi et al., “Microbial Growth Inhibition by Alternating Electric Fields,” Antimicrobial Agents and Chemotherapy, vol. 52, No. 10, pp. 3517-3522, Oct. 2008.
[cited by applicant]
Unknown, “T.R. Shantha, M.D., Prosecuted for Fraud,” www.quackwatch.org/cases/doj/shantha/indictment, Feb. 2008.
[cited by applicant]